Targeting HER2 has resulted in substantial improvements to disease outcomes in patients with HER2+ breast cancer. New combinations and novel approaches aim to further exploit tumors with this biomarker, creating the potential for uncertainty in ideal sequencing of regimens and challenges in aligning practice with emerging evidence and guideline recommendations. Join our esteemed breast cancer specialists for Part 5 of our Breast Cancer Hot Topics series as they walk you through: evidence-driven treatment selection for patients with HER2+ breast cancer appropriate adverse event management for HER2-targeted agents challenging real-world cases. This activity is delivered in partnership with After Breast Cancer Diagnosis (ABCD).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/updated-treatment-paradigms-her2-plus-breast-cancer
- Start Date: 2024-10-04 05:00:00
- End Date: 2024-10-04 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 11250.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 11250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 8291.67 - Is Kind Support: False Source: Merck (Any division) - Amount: 8333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest